Isovorin (Levoleucovorin)

Levoleucovorin is a reduced folate that bypasses the dihydrofolate reductase step, directly replenishing tetrahydrofolate pools needed for DNA synthesis. This protects normal cells from methotrexate‑induced folate depletion and stabilises the binding of fluoropyrimidines to thymidylate synthase, improving their anticancer activity.

The dosage of Isovorin is individualized and determined by the prescribing clinician based on the specific chemotherapy regimen, patient weight, renal function, and treatment context. Healthcare professionals should follow local guidelines and the product label when calculating the appropriate amount.

Safety data for levoleucovorin in pregnancy and lactation are limited. It should only be used when the potential therapeutic benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss risks with their healthcare provider.

To request Isovorin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

The primary alternative is leucovorin (folinic acid), which is a racemic mixture of levoleucovorin and its inactive enantiomer. Levoleucovorin provides a more pharmacologically active form, potentially allowing lower doses and reduced variability in rescue efficacy compared with the racemic preparation.

Isovorin should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from direct light, moisture and extreme temperature fluctuations. Inspect the vial for particulate matter or discoloration before use and discard if any abnormalities are observed.

Isovorin is supplied as a sterile solution for intramuscular or intravenous injection. The route, infusion rate and timing are determined by the treating physician, usually given shortly after high‑dose methotrexate or concurrently with fluoropyrimidine chemotherapy according to protocol.

Serious adverse events include severe hypersensitivity reactions such as anaphylaxis, acute renal failure, significant hepatic injury, and hematologic disturbances like neutropenia or thrombocytopenia. Prompt recognition and medical intervention are essential if any of these reactions occur.

Isovorin is contraindicated in patients with known hypersensitivity to levoleucovorin or any component of the formulation. Caution is also advised for individuals with severe renal or hepatic impairment, as well as for those receiving incompatible chemotherapy agents without appropriate monitoring.